retatrutide trials weight loss (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Eli Lilly infiltrates anti-obesity market

Researchers note that such levels of weight loss could shift expectations around how metabolic signalling pathways, often modulated by peptide-based therapies, can be engaged for deep, sustained effects

If a product description includes spelling errors or terms such as compounded, generic version or same active ingredient as [brand name], it often indicates that the product is a compounded formulation

Fighting a digital hydra The Pharmaceutical Task Group , an industry body representing organised pharmacy and manufacturing interests, views this underground trade as a direct violation of the laws protecting the South African public

Governance insight: The expansion of GLP-1 indicationsfrom diabetes to obesity to cardiovascular protection to sleep apnea to liver diseasewill increasingly challenge the artificial distinction between "covered" and "excluded" uses

This is not unusual and reflects the complex interplay of slowed gastric emptying (which promotes constipation) and altered intestinal motility (which can trigger diarrhea)

Concentration = 10,000mcg 2mL = 5,000mcg/mL